ferrous-fumarate and ferrous-gluconate

A systematic review was conducted to analyze the tolerability of several oral iron supplements based on data obtained in available publications and to report the incidence of adverse effects (AEs) for each supplement both overall and gastrointestinal.. Electronic databases - Medline, the Cochrane Library, and Embase were searched for studies published up to January 2009. Clinical or observational studies reporting data on the tolerability of oral iron supplements were included. Results were described statistically and a quasi-binomial logistic regression model was developed to evaluate and compare the tolerability of the supplements studied.. For this review 111 studies were included, with data on 10,695 patients. Ferrous sulfate with mucoproteose had the lowest incidence of AEs (4.1% for overall AEs, 3.7% for gastrointestinal AEs [GAEs]) and was used as the reference supplement in the regression model. Incidence rates of overall AEs for the other supplements were 7.3% for iron protein succinylate [GAEs: 7%; OR for AE compared to the reference supplement, 1.96], 23.5% for ferrous glycine sulfate [GAEs: 18.5%; OR: 5.90], 30.9% for ferrous gluconate [GAEs: 29.9%; OR: 11.06], 32.3% for ferrous sulfate without mucoproteose [GAEs: 30.2%; OR: 11.21], and 47.0% for ferrous fumarate [GAEs: 43.4%; OR: 19.87]. The differences in incidence of AEs between extended-release ferrous sulfate with mucoproteose and all other supplements except iron protein succinylate were statistically significant at p < 0.001. These findings are subject to some limitations as the designs and methodologies of the studies included show heterogeneity among them that has partially been counteracted by the large sample size provided by the substantial number of trials, which is considered a strength in tolerability studies.. Extended-release ferrous sulfate with mucoproteose appears to be the best tolerated of the different oral iron supplements evaluated.

Topics: Anemia, Iron-Deficiency; Dietary Supplements; Ferric Compounds; Ferrous Compounds; Glycine; Humans; Metalloproteins; Succinates

Iron deficiency (ID) is one of the most common postoperative deficiencies that may develop after Roux-en-Y gastric bypass (RYGB). The optimal mode of treatment is uncertain.. To compare the efficacy of oral ferrous fumarate (FF), oral ferrous gluconate (FG), and a single intravenous infusion of ferric carboxymaltose (FCM) in women with ID after RYGB.. Multicenter randomized controlled trial including 120 women with a serum ferritin <20 μg/l during follow-up after RYGB. They were randomized into three groups: 41 patients were treated with FF 200 mg three times a day (total daily dose: 195 mg elemental iron), 39 received FG 695 mg twice a day (total daily dose: 160 mg elemental iron) for three months, and 39 patients were treated with a single intravenous dose of FCM (1000 mg elemental iron). Serum ferritin levels were measured at six weeks, and three, six and twelve months after the start of supplementation.. At three months, persistence of ID was observed in 29.4% and 42.4% of the patients treated with FF and FG, respectively, but in none of those treated with FCM (p < 0.001). Over the next nine months, recurrence of ID was observed in 56.5% of patients treated with FF, in 52.9% treated with FG, and in 27.8% of those treated with FCM. Adverse effects were most common during oral treatment.. In women developing ID after RYGB, a single dose of intravenous FCM is more effective and better tolerated than the standard treatment with either FF or FG.. The study was registered at clinicaltrials.gov under number NCT02271997.

Topics: Administration, Intravenous; Administration, Oral; Adult; Dietary Supplements; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Gastric Bypass; Humans; Iron Compounds; Iron Deficiencies; Maltose; Postoperative Complications; Treatment Outcome

Impaired uteroplacental perfusion has been shown to play a role in the pathogenesis of some complicated pregnancies with placenta insufficiency. Apart from this, lower oestrogen, magnesium and zinc are found in many of these conditions in the third trimester with placenta insufficiency. In this study, we examined the effect of a 4 mg intravenous dexamethasone injection on estriol, since maternal cortisol or synthetic corticosteroids cross the placental barrier and inhibit the release of dehydroepiandrostesone sulfate in the fetal adrenals. Dexamathasone was found to suppress estriol levels in all groups but a significant difference in suppression was found between the Chemiron--a new combination hematinic--and the control single iron therapy groups. Our preliminary results showed that Chemiron has a protective effect on the development of placenta insufficiency during the third trimester of pregnancy.

Topics: Adult; Anemia; Ascorbic Acid; Dexamethasone; Drug Combinations; Estriol; Female; Ferrous Compounds; Folic Acid; Hematinics; Humans; Magnesium Sulfate; Placental Insufficiency; Pregnancy; Pregnancy Tests; Pregnancy Trimester, Third; Vitamin B 12; Zinc Sulfate

A 61-day short-term prospective study comparing the efficacy of Chemiron capsules (Ferrous Fumarate 300 mg, Folic Acid 5 mg, Vitamin B12 10 ug, Vitamin C 25 mg, Magnesium sulphate, 0.3 mg and Zinc Sulphate 0.3 mg) with conventional ferrous gluconate and folic acid administration has shown that both haematinic regimens improve haematological indices in normal pregnant women. A significant rise in haemoglobin was seen in the Chemiron group on days 5 and 19 whereas a significant increase in packed cell volume was observed on days 5, 19 and 61. There were no significant differences between the mean value of platelets during the therapy period in either group. A significant rise in the mean reticulocyte values could be demonstrated in the Chemiron group throughout the study period. This study further shows that Chemiron has a better haematological effect than Ferrous Gluconate at the dosage used.

Topics: Adolescent; Adult; Ascorbic Acid; Drug Combinations; Female; Ferrous Compounds; Folic Acid; Hematocrit; Hemoglobins; Humans; Iron; Magnesium Sulfate; Nigeria; Platelet Count; Pregnancy; Prospective Studies; Reticulocyte Count; Vitamin B 12; Zinc Sulfate

Iron deficiency anemia is a relatively common illness that can arise from a number of different causes. Three ferrous salts are usually used in its treatment: ferrous fumarate, gluconate, and sulfate. They are administered orally and are relatively well tolerated. These hematinics have been studied by Mössbauer spectroscopy and X-ray powder diffraction, and can easily be distinguished by both techniques. It was found that the two ferrous sulfates studied (Eckerd and SmithKline Beckman Co.) most closely resemble the monohydrate by comparison of the X-ray powder pattern with those of the JCPDS. Both the ferrous fumarate (Femiron) and gluconate (Spring Valley) had approximately 10% ferric iron present. To the authors' knowledge, this is the first reported Mössbauer spectrum for ferrous fumarate.

Topics: Ferrous Compounds; Hematinics; Spectroscopy, Mossbauer; X-Ray Diffraction

Acute accidental iron poisoning is a common serious and potentially fatal intoxication in the young child. Approximately 1 per cent of such poisonings have a fatal outcome, and outcome is closely related to the early onset of coma or shock. Long-term prognosis is excellent for all survivors of the acute episode, although there are occasional obstructive complications occurring four to six weeks later.

Topics: Acute Disease; Animals; Cardiovascular Diseases; Central Nervous System Diseases; Child; Child, Preschool; Deferoxamine; Diagnosis, Differential; Emergencies; Ferrous Compounds; Gastric Lavage; Gastrointestinal Diseases; Humans; Infant; Ipecac; Iron; Prognosis; Risk; Time Factors; Triage